Sutura Therapeutics Appoints Mark Beards as Chief Executive Officer
Birkenhead, England, April 1, 2020: Sutura Therapeutics Limited has announced that Mark Beards has been appointed as Chief Executive Officer. He assumes this role from his prior role as Non-Executive Director of the Company.
Mark is an Industry veteran with more than 25 years' experience. He has previously held a broad range of roles across the value chain of biotechnology and pharmaceuticals, including as CEO at Utility Therapeutics, Group CFO at Celixir plc, and additionally at KPMG, Charles River Associates, Goldman Sachs, McKinsey & Company, GSK and Abbott Laboratories.
“As I have worked with the team at Sutura since joining the Board, I have been impressed by both the Company’s technology, and by the values the people within it hold dear. I am honoured to lead such a company, that truly puts patients at the core of everything we do,” said Mark.
"I welcome Mark’s appointment to a full-time role as CEO as we establish Sutura. Mark’s experience and enthusiasm for improving patient treatment options will drive the company forward and I very much look forward to working with him in the coming years," said James Noble, Sutura’s Board Chairman.
“I am thrilled to welcome Mark as CEO at Sutura, his enthusiasm and knowledge of the industry coupled with strong leadership and patient first values will no doubt help put an end to Duchenne Muscular Dystrophy and many other similarly awful conditions.,” commented Alex Smith, Trustee and Founder of Harrison’s Fund, and Patient Advocacy Advisor to the Company.
Mark holds a BA and MA in Mathematics from The Queen’s College, Oxford, and is a qualified Chartered Management Accountant.